Abstract
We review the practical importance of lobar atrophy in frontotemporal dementia (FTD), for diagnosis and prognosis. We discuss specific patterns of frontotemporal atrophy that denote clinical and pathological subtypes of FTD (e.g. semantic dementia). We also discuss the unsatisfactory clinical experience of interpreting MRI scans in individual FTD cases, especially the behavioural presentations (without aphasic or motor impairments). This issue is explored by examining the FTD phenocopy concept. Lobar atrophy emerges as a key observation in defining behavioural FTD patients whose symptoms are likely to progress. In a situation where objective clinical data are few, we highlight the importance of applying caution before diagnosing FTD is the absence of visible brain atrophy.
Keywords: Frontotemporal dementia, lobar atrophy, phenocopy, PiD, frontal degeneration, CBD, MND features, bvFTD, degenerative pathologies, SD-mimic, gross anatomical change, hippocampal atrophy, PNFA, predominant temporal atrophy
Current Alzheimer Research
Title: Lobar Atrophy in Frontotemporal Dementia: Diagnostic and Prognostic Implications
Volume: 8 Issue: 3
Author(s): R. R. Davies and C. M. Kipps
Affiliation:
Keywords: Frontotemporal dementia, lobar atrophy, phenocopy, PiD, frontal degeneration, CBD, MND features, bvFTD, degenerative pathologies, SD-mimic, gross anatomical change, hippocampal atrophy, PNFA, predominant temporal atrophy
Abstract: We review the practical importance of lobar atrophy in frontotemporal dementia (FTD), for diagnosis and prognosis. We discuss specific patterns of frontotemporal atrophy that denote clinical and pathological subtypes of FTD (e.g. semantic dementia). We also discuss the unsatisfactory clinical experience of interpreting MRI scans in individual FTD cases, especially the behavioural presentations (without aphasic or motor impairments). This issue is explored by examining the FTD phenocopy concept. Lobar atrophy emerges as a key observation in defining behavioural FTD patients whose symptoms are likely to progress. In a situation where objective clinical data are few, we highlight the importance of applying caution before diagnosing FTD is the absence of visible brain atrophy.
Export Options
About this article
Cite this article as:
R. Davies R. and M. Kipps C., Lobar Atrophy in Frontotemporal Dementia: Diagnostic and Prognostic Implications, Current Alzheimer Research 2011; 8(3) . https://dx.doi.org/10.2174/156720511795563818
DOI https://dx.doi.org/10.2174/156720511795563818 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
A High-Throughput Screening Assay for Determining Cellular Levels of Total Tau Protein
Current Alzheimer Research LC-MS/MS Determination of Bromperidol in Biological Matrices: Method Validation and Forensic Application
Current Pharmaceutical Analysis An Overview of EEG Seizure Detection Units and Identifying their Complexity- A Review
Current Signal Transduction Therapy Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research Aging and DNA Methylation
Current Chemical Biology Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Editorial
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacological Evaluation of the Recuperative Effect of Morusin Against Aluminium Trichloride (AlCl3)-Induced Memory Impairment in Rats
Central Nervous System Agents in Medicinal Chemistry Applying Melanopic Lux to Measure Biological Light Effects on Melatonin Suppression and Subjective Sleepiness
Current Alzheimer Research Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Autonomic Sudomotor Dysfunction in Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Atheromatosis Extent in Coronary Artery Disease is not Correlated with Apolipoprotein-E Polymorphism and its Plasma Levels, but Associated with Cognitive Decline
Current Alzheimer Research Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery How and When Environmental Agents and Dietary Factors Affect the Course of Alzheimers Disease: The “LEARn” Model (Latent Early-Life Associated Regulation) May Explain the Triggering of AD
Current Alzheimer Research Doing the Puzzle of Steroid Hormone Action: Biological Functions, Physiological and Clinical Significance of Plasma Membrane-Residing Glucocorticoid Recognizing Proteins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Is Formaldehyde the Missing Link in AD Pathology? The Differential Aggregation of Amyloid-Beta with APOE Isoforms In Vitro
Current Alzheimer Research Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Predicting Stability of Mild Cognitive Impairment (MCI): Findings of a Community Based Sample
Current Alzheimer Research Alzheimer’s Disease is Associated with Increased Risk of Osteoporosis: The Chongqing Aging Study
Current Alzheimer Research